849217-77-2

Basic information

• Product Name: NA
• Synonyms: CabozantinibImpurity8HCl;Cabozantinib Metabolite M7;CabozantinibImpurity8SodiumSalt;Cabozantinib Des-O-fluoroaniline;1-((4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)carbamoyl)cyclopropane-1-carboxylic acid ;Cyclopropanecarboxylic acid,1-[[[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]amino]carbonyl]-
• CAS NO: 849217-77-2
• Molecular Formula: C22H20N2O6
• Molecular Weight: 408.404
• Mol File: 849217-77-2.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: NA(CAS DataBase Reference)
• NIST Chemistry Reference: NA(849217-77-2)
• EPA Substance Registry System: NA(849217-77-2)

Safety Data

• Hazardous Substances Data: 849217-77-2(Hazardous Substances Data)

Usage

Uses

Cabozantinib Des-O-fluoroaniline is a degradation product of Cabozantinib(C051500). Cabozantinib is a small molecule C-Met modulator. Cabozantinib shows dose-dependent inhibition of tumor growth and tumor regression, associated with disruption of the tumor vasculature and extensive tumor cell apoptosis.

Upstream product

• 40258-99-9 1-(chlorocarbonyl)cyclopropane-1-carboxylic acid 
• 190728-25-7 4-((6,7-dimethoxyquinolin-4-yl)oxy)aniline 
• 598-10-7 cyclopropane-1,1-dicarboxylic acid 
• 113020-21-6 1,1-cyclopropanedicarboxylic acid monomethyl ester 
• 123-30-8 4-amino-phenol 
• 1559-02-0 diethyl cyclopropane-1,1-dicarboxylate 
• 3697-66-3 1,1-cyclopropanedicarboxylic acid monoethyl ester 
• 35654-56-9 6,7-dimethoxy-4-chloroquinoline 
• 13425-93-9 6,7-dimethoxyquinoline-4-ol 

Downstream Products

• 1628530-38-0 ortho-hydroxycabozantinib 
• 1628530-41-5 meta-hydroxycabozantinib 
• 849218-30-0 N-[4-(aminomethyl)phenyl]-N'-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)cyclopropane-1,1-dicarboxamide trifluoroacetate 

Relevant articles and documents

BICYCLIC COMPOUNDS AS KINASE MODULATORS, METHODS AND USES THEREOF

The present disclosure relates to derivatives of bicyclic compounds and their uses in therapy. In particular, the present disclosure relates to derivatives of bicyclic compounds for use in modulating kinase enzymatic activity and accordingly modulating kinase-dependent diseases and conditions such as cancer and in specific embodiments, hepatocellular carcinoma (HCC). The present disclosure also relates to methods of synthesizing these compounds.

Preparation method of impurities in synthesis of cabozantinib malate

Belonging to the field of chemical pharmacy, the invention discloses a preparation method of impurities in synthesis of cabozantinib malate. The impurities include KB-2-A, KB-A and SM-3-B. The invention also provides a preparation method of impurity KB-2-

A tyrosine kinase inhibitor and wherein the intermediate preparation method

The invention relates to a preparation method for a tyrosine kinase inhibitor and a midbody thereof. According to the method, a compound 1,1-cyclopropane dicarboxylic acid diester is taken as a raw material, and 1-((4-((6,7-dimethoxy quinoline-4-yl) oxy)